MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
1.050
+0.030
+2.94%
After Hours: 1.030 -0.02 -1.90% 19:53 12/31 EST
OPEN
1.020
PREV CLOSE
1.020
HIGH
1.050
LOW
1.020
VOLUME
301.20K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
0.9657
MARKET CAP
11.30M
P/E (TTM)
-0.3847
1D
5D
1M
3M
1Y
5Y
1D
Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares
Reuters · 12/29/2025 13:10
Weekly Report: what happened at PHIO last week (1222-1226)?
Weekly Report · 12/29/2025 09:57
Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026
NASDAQ · 12/24/2025 11:31
Phio Advances PH-762 With FDA-Backed Toxicology Study
TipRanks · 12/23/2025 14:15
PHIO PHARMACEUTICALS CORP - NO DOSE-LIMITING TOXICITIES IN PH-762 TRIAL - SEC FILING
Reuters · 12/23/2025 13:53
PHIO PHARMACEUTICALS CORP - INITIATIVES CONTINUING TO ADVANCE DELIVERY OF COMMERCIALLY VIABLE DRUG PRODUCT IN 2026
Reuters · 12/23/2025 13:53
PHIO PHARMACEUTICALS CORP - PH-762 HAS BEEN WELL TOLERATED IN ALL ENROLLED PATIENTS IN EACH ESCALATING DOSE COHORT
Reuters · 12/23/2025 13:53
Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results
Benzinga · 12/23/2025 13:47
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.